Correction for RFA-DK-06-004: Biomarker Development for Diabetic Complications (R21)

Notice Number: NOT-DK-06-024

Key Dates
Release Date: November 27, 2006

Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (http://www.niddk.nih.gov/)
National Eye Institute (NEI) (http://www.nei.nih.gov/)
National Heart, Lung, and Blood Institute (NHLBI) (http://www.nhlbi.nih.gov/index.htm)

The purpose of this announcement is to correct the following bullet in RFA-DK-06-004, under Section IV 6. Other Submission Requirements:

  • R21 applications will use the modular budget format and "Just-in-Time" concepts, with direct costs requested in $25,000 modules, up to the total direct costs limitation of $275,000 over an R21 two-year period. No more than $200,000 in direct costs will be allowed in any single year.

The corrected bullet should read.

  • R21 applications will use the modular budget format and "Just-in-Time" concepts, with direct costs requested in $25,000 modules. No more than $250,000 in direct costs will be allowed in any single year.

The correct information about the size of the budget and length of the award is given in Section II 2. Funds Available and remains unchanged.

In most cases, an applicant may request a project period of up to 2 years and a total budget for direct costs up to $300,000 for the entire project. These projects will be funded under the Special Type 1 Diabetes appropriation that ends in 2008. Therefore, projects can only request two years of funding. An exception would be clinical studies that might request a third year at reduced costs for data analysis. Applicants may request a total of $600,000 in direct costs with budgets not exceeding $250,000 in any one year for clinical studies involving expensive imaging studies or measurements on a large number of stored clinical specimens.

All other aspects of RFA-DK-06-004 remain unchanged. The full text of the RFA, which was published on April 19, 2006, can be accessed at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-06-004.html

Inquiries
For further information regarding this notice, please contact:

Teresa L.Z. Jones, M.D.
Program Director for Diabetic Complications
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
6707 Democracy Boulevard, Room 653
Bethesda, Maryland 20892-5460
Telephone: 301-435-2996
FAX: 301-480-3503
E-mail: tj104e@nih.gov